Treatment of type 2 diabetes mellitus and the incretin system.
Whitehill
Dawn
D
SDSU College of Pharmarcy, USA.
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D014481:United States; D014688:Venoms / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D010455:Peptides; D011719:Pyrazines; D013453:Sulfonylurea Compounds; D014230:Triazoles; D014688:Venoms; D008687:Metformin; D000077270:Exenatide; D000068900:Sitagliptin Phosphate